阿尔兹海默医药公司商业计划书英文.docVIP

First, the general theory Alzheimers disease has become the leading killer in elderly health in China. It has become the second most common cause of life-threatening disease in the elderly after cardiovascular disease, cancer and stroke. Statistics show that the mortality rate of dementia up to 57.6% in China. Alzheimers disease accounts for about 50% to 70% of dementia cases. Alzheimers disease is an onset of occult progressive degenerative neurodegenerative disease that occurs in old age and pre-old age. The incidence of Alzheimers disease in China is the same as that of the international community. This incidence multiplied by 200 million elderly population base, you can estimate the number of people with Alzheimers disease in China between 8 million to 10 million. Currently, the number of patients with Alzheimers disease in China has ranked first in the world, while only 21% of patients have been standardized diagnosis. It has always been the focus of peoples attention to the industry. Since the opening of Chinas reform and opening up, the diversification of investment entities in Chinas pharmaceutical industry and the rapid development of medical technology have made it possible for the Chinese pharmaceutical companies. It has laid a good foundation for the rapid development of Chinas pharmaceutical industry. However, at the same time, due to the influence of macroeconomic regulation and control, disorderly development and other factors, a series of unfavorable factors such as the internal capital of the pharmaceutical industry, unreasonable resource structure and unscientific product structure have seriously hindered the rapid development of the pharmaceutical industry. However, the rate of diagnosis and treatment of Alzheimers disease is strongly contrary to the incidence, with only 22% of patients with Alzheimers disease and other types of dementia globally diagnosed. In China, the proportion is even lower. 49% of cases are mistaken for natural aging. Only 2